Skip to main content
SpringerLink
Log in

Pharmacokinetics of Cefoperazone: A Review

  • Session II
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The pharmacokinetics of cefoperazone in normal subjects, and in patients with hepatic and renal dysfunction are reviewed. After intravenous administration of 2g of cefoperazone, levels in serum ranged from 202 to 375µg/ml depending on the period of drug administration. After intramuscular injection of 2g of cefoperazone, the mean peak serum level was 11 1µg/ml at 1.5 hours. At 12 hours after dosing, mean serum levels were still 2 to 4µg/ml. Cefoperazone was 90% bound to serum proteins. The apparent volume of distribution was 10 to 13L. The half-life of the drug varied from 1.6 to 2.4 hours; serum clearance was between 75 and 96ml/min. Urinary excretion was rapid, but only 15 to 36 % of the cefoperazone dose was recovered in the urine. Renal clearance ranged from 14 to 25ml/min. Urine levels of cefoperazone in excess of 32µg/ml were maintained for at least 12 hours. Biliary levels of cefoperazone were many-fold higher than serum levels; peak bile concentrations from 675 to 6000µg/ml were obtained.

Severe hepatic dysfunction was associated with a 2- to 4-fold increase in the half-life of cefoperazone. In patients with relatively complete biliary obstruction, over 90 % of the dose was recovered in the urine. In contrast, the serum kinetics of cefoperazone were not significantly altered in patients with renal impairment.

The human pharmacology of cefoperazone is similar to cephazolin in terms of serum concentrations, half-life, protein binding, and apparent volume of distribution, but markedly different in terms of biliary and renal excretion. Since biliary excretion is normally the primary route of cefoperazone elimination, dosage modification should only be required in the presence of severe biliary obstruction or concomitant renal and hepatic dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Allaz, A.F.; Dayer, P.; Fabre, J.; Rudhardt, M. and Balant, L.: Pharmacokinetics of a new cephalosporin, cefoperazone. Schweizerische Medizinische Wochenschrift 109: 1999–2005 (1979).

    PubMed  CAS  Google Scholar 

  • Aoki, N.; Sekine, O.; Usuda, Y.; Shimizu, T.; Hirasawa, Y. and Aoki, T.: Serum, urine, and bile levels of cefoperazone (T-1551); in Nelson and Grassi (Eds) Current Chemotherapy and Infectious Disease, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Vol. 1, pp. 159–161 (American Society for Microbiology, Washington DC 1980).

    Google Scholar 

  • Arnold, J.D.; March, L. and Berger, A.: Multi-dose comparison of cefoperazone and cefamandole (abstr.). Symposium on Cefoperazone: A Clinical Review; New Orleans, Louisiana, September 21 (1980).

  • Balant, L.; Dayer, P.; Rudhardt, M.; Allaz, A. and Fabre, J.: Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and the pharmacokinetics in rats. Clinical Therapeutics 3: 50–59 (Special Issue, 1980).

    PubMed  CAS  Google Scholar 

  • Bolton, W.K., Michael, W.M. and Merle, M.A.: Pharmacokinetics of cefoperazone in patients with renal insufficiency (abstr.). Symposium on Cefoperazone: A Clinical Review; New Orleans, Louisiana, September 21 (1980).

  • Bundtzen, R.; Craig, W.; Toothaker, R.; Brodey, M.; Gerber, A. and Welling P.: Cefoperazone: Single dose pharmacokinetics (abstr. 112). 20th Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans, Louisiana, September 22–24 (1980).

  • Craig, W.A.: Single dose pharmacokinetics of cefoperazone following intravenous administration. Clinical Therapeutics 3: 46–49 (Special Issue, 1980).

    PubMed  CAS  Google Scholar 

  • Craig, W.A.; Gerber, A.U.; Barbhaiya, R.H. and Welling, P.G.: Pharmacokinetics of cefoperazone in patients with hepatic dysfunction (abstr.). Symposium on Cefoperazone: A Clinical Review; New Orleans, Louisiana, September 21 (1980).

  • Foster, T.S.; Batenhorst, R.L.; Raehl, C.L.; Wilson, H.D.; Goodman, N.L.; Haack, D.G. and McKean, H.E.: Pharmacokinetics of cefoperazone and the effect on bowel function and flora (abstr.). Symposium on Cefoperazone: A Clinical Review; New Orleans, Louisiana, September 21 (1980).

  • Hoffstedt, B.; Walder, M. and Cronberg, S.: Penetration of cefradine (CFN), cefuroxime (CXM), cefoxitin (CXN), and cefoperazone (CFZ) into interstitial fluid (IF) and its relation to mode of administration in man (abstr. 172). 20th Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans, Louisiana, September 22–24 (1980).

  • Lode, H.; Belmega, G.; Jendroschek, T.; Borner, K. and Koeppe, P.: Comparative pharmacokinetics of cefoperazone, cefotaxime and moxalactam (abstr.). Symposium on Cefoperazone: A Clinical Review; New Orleans, Louisiana, September 21 (1980a).

  • Lode, H.; Kemmerich, B.; Koeppe, P.; Belmega, D. and Jendroschek, H.: Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin. Therap. 3: 80–88 (Special Issue, 1980b).

    CAS  Google Scholar 

  • Matsumoto, K.; Uzuka, Y.; Shishido, H.; Nagatake, T. and Suzuki, H.: Clinical and laboratory evaluation of cefoperazone (T-1551) in respiratory infections; in Nelson and Grassi (Eds) Current Chemotherapy and Infectious Disease, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Vol. 1, pp.169–170 (American Society for Microbiology, Washington DC 1980).

    Google Scholar 

  • Reeves, D.S.; Bywater, M.J.; Holt, H.A.; White, L.O.; Davies, A.J.; Elliott, P.J. and Foulds, G.: Pharmacokinetics of cefoperazone in man (abstr. 113). 20th Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans, Louisiana, September 22–24 (1980).

  • Rosenfeld, M.B.; Ratzan, K.R. and Lauredo, I.: A comparison of the biliary tract excretion of cefoperazone and cefamandole (abstr. 114). 20th Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans, Louisiana, September 22–24 (1980).

  • Sambe, B.; Jo, K. and Inafuku, M.: Fundamental and clinical studies of cefoperazone (T-1551) in otorhinolaryngological infections; in Nelson and Grass (Eds) Current Chemotherapy and Infectious Disease, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Vol. 1, pp. 172–174 (American Society for Microbiology, Washington DC 1980).

    Google Scholar 

  • Sasaki, J.; Goto, J.; Konnai, T.; Miyachi, S.; Yamada, Y.; Imoto, T.; Kobune, H. and Takeyasu, H.: Pharmacokinetics of cefoperazone (T-1551); in Nelson and Grassi (Eds) Current Chemotherapy and Infectious Disease, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Vol. 1, pp.174–176 (American Society for Microbiology, Washington DC 1980).

    Google Scholar 

  • Shimizu, K.: Absorption, excretion, distribution and metabolism; in New Drug Symposium I: T-1551 (cefoperazone), pp.57-96. The 27th General Congress of Japan Society of Chemotherapy. Fukuouka City, Japan, June 7 (1979).

  • Shimizu, K.: Cefoperazone: Absorption, excretion, distribution and metabolism. Clinical Therapeutics 3: 60–79 (Special Issue, 1980).

    PubMed  CAS  Google Scholar 

  • Srinivasan, S.; Francke, E.L. and Neu, H.C.: Comparative pharmacokinetics of moxalactam, cefoperazone, cefotaxime, cefamandole and cefazolin in normal individuals (abstr. 241). 20th Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans, Louisiana, September 22–24 (1980a).

  • Srinivasan, S.; Francke, E.L.; Appel, G.B:; Salzman, M. and Neu, H.C.: The pharmacokinetics of moxalactam, cefotaxime and cefoperazone in patients with renal insufficiency and undergoing hemodialysis (abstr. 246). 20th Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans, Louisiana, September 22–24 (1980b).

  • Watanabe, Y.; Takashita, H.; Hayashi, T.; Yasuda, T.; Saikawa, I. and Shimizu, K.: Studies on protein binding of cefoperazone (T-1551); in Nelson and Grassi (Eds) Current Chemotherapy and Infectious Disease, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Vol. 1, pp. 161–163 (American Society for Microbiology, Washington DC 1980).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine, Medical Service, William S. Middleton Memorial Veterans Administration Hospital and University of Wisconsin, 2500 Overlook Terrace, Madison, Wisconsin, 53705, USA

    William A. Craig & Andreas U. Gerber

Authors
  1. William A. Craig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas U. Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Craig, W.A., Gerber, A.U. Pharmacokinetics of Cefoperazone: A Review. Drugs 22 (Suppl 1), 35–45 (1981). https://doi.org/10.2165/00003495-198100221-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198100221-00010

Keywords

Search

Navigation